John Koo

19.1k total citations · 3 hit papers
339 papers, 12.5k citations indexed

About

John Koo is a scholar working on Immunology, Dermatology and Clinical Psychology. According to data from OpenAlex, John Koo has authored 339 papers receiving a total of 12.5k indexed citations (citations by other indexed papers that have themselves been cited), including 206 papers in Immunology, 179 papers in Dermatology and 55 papers in Clinical Psychology. Recurrent topics in John Koo's work include Psoriasis: Treatment and Pathogenesis (200 papers), Dermatology and Skin Diseases (142 papers) and Body Image and Dysmorphia Studies (52 papers). John Koo is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (200 papers), Dermatology and Skin Diseases (142 papers) and Body Image and Dysmorphia Studies (52 papers). John Koo collaborates with scholars based in United States, Canada and Denmark. John Koo's co-authors include Mark Lebwohl, Alan Menter, Steven R. Feldman, Alice B. Gottlieb, Reva Bhushan, Craig A. Elmets, Neil J. Korman, Kenneth B. Gordon, Karl R. Beutner and Abby S. Van Voorhees and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Clinical Infectious Diseases.

In The Last Decade

John Koo

322 papers receiving 11.8k citations

Hit Papers

Guidelines of care for the management of psoriasis and ps... 2001 2026 2009 2017 2008 2001 2008 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Koo United States 55 8.0k 6.8k 1.7k 1.4k 1.1k 339 12.5k
P.C.M. van de Kerkhof Netherlands 61 8.9k 1.1× 8.0k 1.2× 1.8k 1.1× 2.0k 1.4× 1.3k 1.2× 498 15.9k
Alexa B. Kimball United States 64 9.2k 1.2× 10.1k 1.5× 2.1k 1.2× 1.7k 1.2× 1.5k 1.4× 364 17.4k
Ulrich Mrowietz Germany 60 7.5k 0.9× 5.9k 0.9× 1.4k 0.8× 1.5k 1.0× 1.4k 1.3× 331 12.7k
Lone Skov Denmark 58 6.6k 0.8× 5.5k 0.8× 1.9k 1.1× 1.1k 0.8× 1.7k 1.5× 389 12.9k
Craig L. Leonardi United States 45 11.4k 1.4× 6.4k 0.9× 2.6k 1.5× 2.0k 1.4× 2.0k 1.8× 133 14.1k
Wolf‐­Henning Boehncke Germany 55 8.7k 1.1× 4.4k 0.6× 2.7k 1.6× 1.3k 0.9× 1.4k 1.2× 356 13.2k
Alan B. Fleischer United States 57 3.1k 0.4× 7.6k 1.1× 937 0.5× 1.0k 0.7× 950 0.9× 332 12.4k
Charles N. Ellis United States 58 4.4k 0.5× 5.9k 0.9× 1.4k 0.8× 1.5k 1.1× 948 0.9× 235 11.6k
Jacek C. Szepietowski Poland 58 3.7k 0.5× 10.6k 1.6× 2.5k 1.5× 1.0k 0.7× 1.7k 1.5× 637 15.3k
L. Misery France 54 2.6k 0.3× 6.4k 0.9× 2.0k 1.2× 727 0.5× 1.8k 1.7× 517 11.5k

Countries citing papers authored by John Koo

Since Specialization
Citations

This map shows the geographic impact of John Koo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Koo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Koo more than expected).

Fields of papers citing papers by John Koo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Koo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Koo. The network helps show where John Koo may publish in the future.

Co-authorship network of co-authors of John Koo

This figure shows the co-authorship network connecting the top 25 collaborators of John Koo. A scholar is included among the top collaborators of John Koo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Koo. John Koo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brownstone, Nicholas, et al.. (2025). Can pimozide kill parasites? Surprisingly, the most honest answer is ‘yes’. Journal of Dermatological Treatment. 36(1). 2466635–2466635.
3.
Cather, Jennifer Clay, Melodie Young, Shehla Admani, et al.. (2025). Genital Psoriasis: Shining Light on This Hidden Disease. JEADV Clinical Practice. 4(4). 719–731.
4.
Bhutani, Tina, et al.. (2024). Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis. Journal of Drugs in Dermatology. 23(8). 612–618. 4 indexed citations
5.
Lebwohl, Mark, John Koo, April W. Armstrong, et al.. (2024). Brodalumab: Six-Year US Pharmacovigilance Report. Dermatology and Therapy. 15(1). 213–222.
6.
Bhutani, Tina, et al.. (2024). Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis. PubMed Central. 1 indexed citations
7.
Alexis, Andrew, Heather Woolery‐Lloyd, Anneke Andriessen, et al.. (2022). Evolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care. Journal of Drugs in Dermatology. 21(10). 1054–1060. 5 indexed citations
8.
Armstrong, April W., Mark Lebwohl, Joseph F. Merola, et al.. (2021). Non-Medical Switching Impact on Patients and Providers – Psoriatic Disease Community Taking a Stand. 6(3). 126–127.
9.
Brownstone, Nicholas, Vidhatha Reddy, Quinn Thibodeaux, et al.. (2020). Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update. 5(3). 82–85. 1 indexed citations
10.
Reddy, Vidhatha, Bridget Myers, Stephanie Chan, et al.. (2020). Management strategies for borderline and narcissistic personality disorders in dermatology practice: a review. Journal of Dermatological Treatment. 33(3). 1265–1268. 1 indexed citations
11.
Myers, Bridget, Vidhatha Reddy, Stephanie Chan, et al.. (2020). Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing. Journal of Dermatological Treatment. 33(1). 87–93. 1 indexed citations
12.
Nakamura, Mio & John Koo. (2020). Safety considerations with combination therapies for psoriasis. Expert Opinion on Drug Safety. 19(4). 489–498. 22 indexed citations
13.
Reddy, Vidhatha, Bridget Myers, Stephanie Chan, et al.. (2020). A review of current phase III clinical trials of plaque psoriasis: under‐representation of nonwhite participants and need for reform. British Journal of Dermatology. 184(2). 348–350. 13 indexed citations
14.
Singh, Rasnik, et al.. (2016). A Quick Review of the Cutaneous Findings of the Zika Virus. Dermatology Online Journal. 22(7). 3 indexed citations
15.
Nakamura, Mio & John Koo. (2016). Drug-Induced Tactile Hallucinations Beyond Recreational Drugs. American Journal of Clinical Dermatology. 17(6). 643–652. 12 indexed citations
16.
Nakamura, Mio, John Koo, & Tina Bhutani. (2016). Uremic pruritus treated successfully with the Goeckerman Program. Dermatology Online Journal. 22(8). 2 indexed citations
17.
Nakamura, Mio, Tina Bhutani, & John Koo. (2016). Narrowband UVB-induced iatrogenic polymorphous light eruption: a case and suggestions to overcome this rare complication. Dermatology Online Journal. 22(6). 3 indexed citations
18.
Wong, Jillian W., Faranak Kamangar, Tien V. Nguyen, & John Koo. (2012). Excimer laser therapy for hairline psoriasis: a useful addition to the scalp psoriasis treatment algorithm.. PubMed. 17(5). 6–9. 5 indexed citations
19.
Koo, John, et al.. (2006). Predictive value of phenotypic variables for skin cancer: Risk assessment beyond skin typing. International Journal of Dermatology. 45(11). 1275–1283. 8 indexed citations
20.
Kim, Young Tae, Eunwoo Nam, Bo Hyun Yoon, et al.. (2005). Germline Mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma. Gynecologic Oncology. 99(3). 585–590. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026